Diphereline

OBJECTIVE: To investigate the effect of 2 medications; Diphereline and Cabergoline, on uterine leiomyoma growth, and its histologic, sonographic, and intra-operative changes. METHODS: In an effort to treat large uterine leiomyoma in symptomatic patients in the Gynecology Clinics of the Alzahra Teaching Hospital of Tabriz University of Medical Sciences, Tabriz, Iran, from September 2007 to November 2008, 60 candidates randomized to receive Diphereline 3.75 mg, 4 times every 28 days (group I), and Cabergoline 0...

INTRODUCTION: Central precocious puberty is usually idiopathic. Appearance of the precocious puberty symptoms in early childhood or pre-school period indicate that also it could be caused by organic disorder of the central nervous system. The aim of this work is to present the case of the 4-year-old girl, diagnosed with precocious puberty. THE CASE REPORT: The first clinical symptoms of precocious puberty such as increased growth rate and breast enlargement were observed when the girl was 4 years old...

OBJECTIVE: To explore the methods of making an animal model with sterilized testes. METHODS: (1) X-ray local irradiation. Seventy 8-10-week-old male mice were equally divided into 6 experiment groups and a control group. The testes of the mice in the 6 experiment groups were irradiated sequentially by 1000, 1200, 1400, 1600, 1800 and 2000 cGy X-ray for 10 minutes, while those in the control group remained untreated. And then the pregnancy test was performed. (2) Cyclophosphamide injection...

OBJECTIVE: To investigate the effect of cabergoline (Dostinex, a dopamine agonist) on the myoma growth compared to Diphereline (a gonadotropin-releasing hormone agonist). METHODS: This study took place in the Department of Obstetrics and Gynecology of Tabriz University of Medical Sciences, Tabriz, Iran from July 2004 to December 2005. Fifty women with uterine myoma, who met the criteria of the study thoroughly, were randomly allocated into 2 equal groups to take either Diphereline or Cabergoline...

Von Recklinghausen's disease belongs to a group of neurocutaneous syndromes and is characterised by skin, nerve and bone abnormalities. We present a case of von Recklinghausen's disease and precocious puberty in 7-year-old boy. At the age of three café au lait spots on the skin and an incranial tumour situated near the optic chiasm--qualified as inoperable--were discovered. At the age of 7 first signs of precocious puberty appeared (pubic hair P3 and enlargement of the testes (15 ml) and penis). Laboratory measurements included: LH 7...

Our purpose was to define the best way of treating tubal infertility caused by endometriosis. We have studied 24 patients with tubal infertility caused by endometriosis; the etiology has been laparoscopically established in the 2nd Clinic of Obstetrics and Gynecology Iaşi. The endometriosis score (r-AFS) was used to establish the therapy. We performed laparoscopic treatment when endometriosis was visible. Postoperative medical therapy (Diphereline, 3 months) was indicated; patients with ,,unpigmented endometriosis" received the same medical therapy...

OBJECTIVE: To investigate the relationship of serum dehydroepiandrosterone (DHEA) levels and female precocious puberty. METHODS: The serum levels of DHEA and dehydroepiandrosterone sulfate (DHEAS) were measured by ELISA in 60 idiopathic central precocious puberty (ICPP) girls, 62 premature thelarche (PT) girls and 31 age-matched health prepuberty girls. Bone age,volume of uterus and ovary, DHEA and DHEAS were re-measured in 3, 12 months after treatment with Diphereline in ICPP girls...

A prospective, randomized, comparative study has been carried out to investigate the effectiveness of administration of recombinant FSH (rFSH, Gonal-F) in doses 150 and 225 IU in different age groups of women. 63 patients started a long gonadotrophin-releasing hormone agonist protocol (GnRHa, Diphereline, 0,1 mg): 31 received rFSH 150 IU/day and 32 - 225 IU/day. The objective was to assess the impact of these dosing regimens in down-regulated women. Duration of treatment for reaching administered criteria for human chorionic gonadotropin (HCG, Profazi) showed that the results in low-dose group and high-dose group were similar (11,8+/-0,2 days versus 11,2+/-0,4 days)...

OBJECTIVE: To evaluate hormonal suppression and pubertal development in children with central precocious puberty (CPP) after injection of triptoreline 11.25 mg (Diphereline S. R. 11.25 mg; Ipsen) in the first treatment cycle of 12 weeks. DESIGN: Pilot study. SETTING: Paediatric department, University Hospital Motol-Prague. METHODS: Serum levels of FSHmax and LHmax and basal levels of estradiol/testosterone were monitored in GnRH test before, 4, 8 and 12 weeks after triptoreline 11...

For the purpose of optimizing the superovulation stimulation and improving clinical outcome, the gonadotropin-releasing hormone (GnRH-a) agonist were successfully used in the in vitro fertilization program. Under observation were 200 women of the reproductive age with the average length of sterility 7,6+/-4,1 years. The causes of sterility were as follows: tubo-peritoneal factor 84 (42%), endometriosis 54 (27%), PCOS 24 (19%), unknown infertility 38 (19%). After the transvaginal puncture, the fertilization rate constituted 136 (67,8%)...

A comparative study was carried out to assess the main criteria of folliculogenesis in follicular fluid of aspirated follicles during the induction of super ovarian stimulation using recombinant follicle stimulating hormone (r-FSH; Gonal-F), human menopausal gonadotropin (HMG, Pergonale) and agonist gonadotropin releasing hormone (a-GnRH; Diphereline 3,75 mg). 86 patients were included in the study: 37 were receiving r-FSH and 49 HMG, two ampoules per day during the first 5 days of stimulation. Ultrasound monitoring was used for every individual follicle on the first day of stimulation and starting from the 5th day, daily...

OBJECTIVE: To determinate the effectiveness of treatment with gonadotrophine releasing hormone agonist. METHODS: We investigated 164 patients with laparoscopy divided in two groups. Women in first group received Dipherelin 3. 75 mg /lpsen/ for 3 months. Second group had received Dipherelin 3.75 mg for 6 months. Preparation was done i.m. every 28 days. All patients in the study had endometriosis grade I-II using the AFS classification after laparoscopy. The measures according to compare in the 2 groups was as following: 1...

No abstract text is available yet for this article.

Our objective in this work was to study efficiency of cryohormonal treatment in patients with internal endometriosis. As many as 27 female patients were treated, in whom the diagnosis of internal endometriosis had been confirmed with the aid of ultrasound investigation, hysteroscopy and laparoscopy. All above patients underwent intrauterine cryodestruction of endometrioidal loci by a contact technique over 3 minutes with subsequent administration of dipherelin, 3.75 mg every 28 days, a total of 4 to 6 injections for the course...